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Abstract
Early activation of coagulation is an important factor in the initiation of innate immunity, as 
characterized by thrombotic microangiopathy (TMA). In transplantation, systemic anti-
coagulation is difficult due to bleeding. A novel ‘cytotopic’ agent, ‘Thrombalexin’, (TLN) 
combines a cell-membrane bound (mirystoyl tail) anti-thrombin (HLL peptide) which can be 
perfused directly to the donor organ or cells.
Thromboelastography (TEG) was used to measure time to clot formation (r-time) in both rhesus 
and human blood, comparing TLN vs. HLL (without cytotopic tail) vs. negative-control. Both 
TLN and HLL treated rhesus or human whole blood result in significantly prolonged r-time 
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compared to kaolin controls. Only TLN-treated human endothelial cells (EC) and neonatal porcine 
islets (NPI) prolonged time to clot formation. Detection of membrane-bound TLN was confirmed 
by immunohistochemistry and FACS. In vivo, perfusion of a NHP kidney TLN-supplemented 
preservation solution in a sensitized model of transplantation demonstrated no evidence of TLN 
systemically. Histologically, TLN was shown to be present up to four days after transplantation. 
There was no platelet deposition and TMA severity, as well as microvascular injury scores 
(glomerulitis + peritubular capillaritis) were less in the TLN treated animals. Despite promising 
evidence of localized efficacy, no survival benefit was demonstrated.
Introduction
Thrombotic microangiopathy (TMA) is a systemic pathological phenomenon of systemic 
thrombocytopaenia, microangiopathic haemolytic anaemia (MAHA) and microvascular 
thrombosis, with local consequences of potential end-organ damage resulting from 
deposition of microthrombi. Although primarily a thrombotic disorder, TMA is 
representative of the crosstalk between coagulation and complement activation, as part of the 
innate immune system (1). Primary TMA has a wide differential diagnosis (2). Following 
renal transplantation, TMA is a phenomenon observed in differing clinical circumstances 
either arising as a result of disease recurrence, such as in haemolytic uraemic syndrome 
(HUS, and atypical HUS), or in antibody mediated rejection(3). Histological features of 
TMA in the transplanted organ range from acute fibrin thrombi and endothelial swelling to 
membranoproliferative lesions, segmental glomerular sclerosis, arteriolar hyalanosis, intimal 
fibrosis and laminated hypertrophy of the arteriolar walls (4, 5). In the revised Banff 
classification from 2013, TMA is one of the histological markers of acute tissue injury 
required for a diagnosis of acute/active antibody mediated rejection (ABMR)(6, 7). Since 
TMA is one of a number of features of ABMR, and not seen in all cases, it may be difficult 
to identify recipients at risk of developing TMA, although it is more frequent in highly 
sensitized models of transplantation (8). Prophylactic treatment at the time of transplantation 
to prevent TMA is difficult with conventional anti-coagulation therapy (heparin, coumarins, 
warfarin) due to the risk of bleeding in the post-operative setting and the requirement for 
systemic treatment and repeated dosing. A localized anticoagulant therapy is therefore 
highly desirable.
Thrombalexin (TLN) is a novel cytotopic anticoagulant suitable for localized treatment of 
donor organ, tissues or cells prior to transplantation. It combines a hirudin-like peptide 
(HLL, based on the thrombin inhibitor, hirudin), with a mirystoyl tail which inserts directly 
into the cell membrane. TLN inhibits thrombin activation only in the location where it is 
applied. Previously, variants of the compound have been used in a hepatocyte model, with 
the goal of overcoming instant blood mediated inflammatory reaction (IBMIR)(9). 
Thrombalexin has also been tested to treat donor organs in a highly sensitized rodent 
transplant model wherein it was shown to increase survival when compared to no 
treatment(10). The mechanism of plasma membrane localization makes Thrombalexin 
ideally suited for treatment of both solid organ and cell-based transplantation. Here we 
report our findings of both in vitro and in vivo efficacy of Thrombalexin, in a highly 
sensitized rhesus model of organ transplantation.
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Materials and Methods
Cells, plasma, and blood preparation
Citrated blood samples from healthy human volunteers and non-human primates were 
approved by Duke University institutional review board (IRB Pro00062495) and Duke 
Institutional Animal Care and Use Committees (IACUC A209-15-07). Platelet poor plasma 
was obtained from citrated whole blood samples, which were spun for 15m at 2700g. 
Following this, the supernatant was further spun for 15 min at 2700g before being frozen 
(−20) prior to use (TLN detection & ELISA). Wild-type neonatal porcine islet (NPI) and 
primary human aortic endothelial cells (EC) were cultured as per supplemental methods.
Animal selection and care
Specific pathogen-free, 3 to 6 year old male rhesus macaques (Macaca mulatta) from Alpha 
Genesis Inc. (Yemassee, SC) were MHC genotyped by deep sequencing at the Genetics 
Services Unit, Wisconsin National Primate Research Center, Madison, WI. Donor-recipient 
pairs were selected by choosing maximal disparity for MHC class I & II. As described 
previously, donor-recipient pairs underwent two serial skin transplants prior to kidney 
transplantation. All animals received depletional induction with anti-CD4 & anti-CD8 mAbs 
(CD4R1 & M-T807R1 NHP Reagent Resource, Mass Biologics, MA) at the time of 
transplant followed by maintenance therapy with tacrolimus, mycophenolate mofetil and 
prednisolone (8). Rhesus monkey kidneys not required for implantation were retrieved as for 
a donor nephrectomy, flushed slowly with 5ml of UW (University of Wisconsin) perfusion 
solution, before being flushed with Thrombalexin (TLN) for ex-vivo detection by IHC, 
following the slow TLN flush, a further 5ml flush of UW was given to remove unbound 
compound. All medication and procedures were conducted in accordance with Duke 
Division of Lab Animal Resources (DLAR), Yerkes National Primate Center, (Atlanta, GA) 
and the National Institutes of Health (Bethesda, MD) guidelines after approval by both Duke 
University (Durham, NC) and Emory University (Atlanta, GA) Institutional Animal Care 
and Use Committees.
Thrombalexin (TLN; PTL060) infusion
Thrombalexin (TLN or PTL060, TLN-3) compound consists of membrane-localizing agent 
(mirystoyl tail) attached to hirudin-derived sequence, ‘HLL’ (a hirudin-like molecule which 
binds both to the active site of thrombin, and has an exosite which interacts with fibrinogen, 
see Figure 1A). A stock solution was prepared, 1mg/ml to give a concentration of 2 μM. A 
compound, (HLL or PTL011) with the hirudin-like molecule but no cytopic tail was used as 
a control, which was also prepared to a 2μM stock solution. Both agents were generously 
supplied by Dr R. Smith, MRC Centre for Transplantation, King’s College, London, and 
were synthesized by Almac Sciences, Craigavon, UK. Following donor nephrectomy, all 
kidneys were perfused via the renal artery with 5–8mls of University of Wisconsin (UW) 
perfusion solution until the effluent from the renal vein was clear. Thrombalexin treated 
animals received TLN 4uM (500 ul of stock solution (1mg/ml) of PTL060, diluted in 5mls 
of UW, followed by an additional flush of UW solution (5ml) to remove any unbound TLN.
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Flow cytometric detection of Thrombalexin (PTL060)
FACS detection of TLN in whole blood or plasma (human or rhesus), EC and PBMC was 
performed using TLN-specific primary antibody (RICS2, 1:500, gift from R. Smith, King’s 
College) and secondary antibodies (goat anti-mouse FITC, AbD Serotec). For full details see 
Supplemental Methods. Flow cytometry was performed on BD LSRFortessa ×20 and 
analyzed using FlowJo (Tree Star, San Carlos, CA) software.
Thromboelastography (TEG)
Thromboelastography (TEG, Haemonetics, IL) uses mechanical motion to provide a 
quantification of whole blood coagulation, where r-time represents the time to clot initiation 
and is a reflection of coagulation factor activity(11). TEG was used to assess the direct effect 
of TLN (or controls) on whole blood (human or rhesus), TLN (or control) treated cells, as 
well as post-transplant evidence of changes in time to clot formation. For full details see 
Supplemental Methods.
IHC and Immunofluorescence staining for Thrombalexin
Tissue sections were submitted for formalin fixed paraffin embedding (FFPE). And stained 
for Haematoxylin & Eosin, C4d (American Research Products), Inc, Whaltham, MA), CD61 
(human platelet glycoprotein IIIa, Sigma-Aldrich, USA) by the core histopathology research 
lab (Duke University, Durham, NC). Interpretation of immunohistochemistry specimens was 
performed by Dr David Howell (Duke University, Durham) this included TMA & CD61 
scoring (1 = mild; 2 = moderate; 3 = severe, 0 = none). Dr Brad Farris (Emory University, 
Atlanta) undertook blinded review of Banff scoring at a secondary institution. For a TLN 
detection, tissue sections were embedded in OCT, rapidly frozen and maintained at −80 
degrees. Frozen section slides were fixed in cold acetone for 20 minutes and air dried. After 
autoquench and blocking steps, primary staining was performed with RICS2 (1:100, primary 
antibody raised in mouse against PTL060, gift from R Smith) and a secondary FITC ab 
(goat-anti-mouse FITC, AD Serotec). For full details, see Supplemental methods. For 
detection of PTL060 on NPI, treated NPI were resuspended in FACS buffer (2% FBS in 
PBS), and treated with primary (RICS, 1: 500) and secondary antibody (goat anti-mouse 
FITC, AbD Serotec, 1: 200) before being added transferred to a slide, using a Cytospin 
machine. For full details, see Supplemental methods. Microscopy was performed on a Leica 
DMRA2 Compound Microscope with OpenLab Software. 10× and 20× objectives were used 
in conjunction with the following fluorescent cubes: DAPI: UV excitation (Ex. DAPI/
Hoechst), HQ:R/Dil: Green excitation (Ex. Rhodamine RITC, Dil and HQ:F: Blue excitation 
(Ex. FITC). Digital images were captured using Volocity software. Confocal imaging was 
performed on a Leica SP5 confocal microscope.
ELISA analysis of C3a, C4d and TCC (C5b-9)
For quantitative analysis, Enzyme linked immunoassays (ELISAs) were performed on 
commercially available kits, according to manufacturers instructions: serum samples were 
tested for C3a (MicroVue, Quidel, San Diego); C4d (MicroVue, Quidel, San Diego); SC5b-9 
(MicroVue, Quidel, San Diego). Plasma samples were tested for TAT (Thrombin-anti-
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Thrombin, Enzygnost, TAT, Siemens); Asserachrom vWF:Ag (Diagnostica Stago, NJ, 
USA). Limited control plasma samples (n = 1) were available for analysis.
Statistical analysis
All data are presented as mean ± standard deviation (error bars in graphs) or as otherwise 
indicated. Sample comparisons of different animals and/or time points were achieved by 
two-tailed (unpaired) t- test in normally distributed data. In case of unequal variances we 
used Welch’s t-test (15). For survival analysis we used the Kaplan-Meier method and log-
rank test. Values of p<0.05 were considered to be statistically significant. We used Prism 6.0 
(GraphPad Software, San Diego, CA)
Results (1123)
Detection of cell membrane-bound Thrombalexin (PTL060) in whole blood
To confirm the binding of TLN to cell membranes, whole blood (NHP and human) was 
spiked with TLN (2μM, 500μM, 125μM, 31.25μM, 7.8μM,1.94μM, 0.4μM, 0.1μM). As 
shown in Figure 1B and C, TLN was detected by RICS2 mAb in both NHP (n=6), and 
human blood (n=6). Membrane bound TLN is detectable at very low levels (~0.1μM, 
p<0.05), which allows for systemic detection of the compound. Time to clot formation, was 
assessed by Thromboelastography (TEG). Citrated blood was treated with TLN (PTL060), 
HLL (PTL011) or control and time to clot initiation (r-time) measured. Interestingly, rhesus 
blood showed a reduced time to clot initiation, compared to human blood, indicating greater 
thrombogenic potential of NHP blood. When added directly to whole blood, both PTL060 
and PTL011 prolonged the r-value in both NHP (Figure 2A) and human blood (Figure 2B), 
indicating anticoagulant effect compared to control. To demonstrate membrane binding of 
Thrombalexin, RICS2 mAb was used to detect PTL060 after endothelial cell (EC) treatment 
with PTL060, PTL011 or PBS alone, (Figure S1). PTL060 alone is detectable on EC after 
treatment and washing. NPIs are not amenable to flow detection without first being lysed, 
hence the immunofluorescent method of detection. Similarly, evidence of PTL060 binding 
to NPI is demonstrated in compared to control or PTL011 treatment (Figure S1).
Prolonged coagulation time by cell-bound Thrombalexin (PTL060) on Endothelial Cells and 
Neonatal Porcine Islets
To confirm the effect of cells incubated with Thrombalexin, r-time of human blood was 
measured with human endothelial cell (EC) alone, PTL011 incubated EC, and PTL060 
incubated EC, as well as NPI. PTL060 incubated EC significantly increased r-time while 
PTL011 incubated EC did not prolonged the coagulation time compared to EC control 
(Figure 2C). Compared to PBS controls, ECs themselves shorten r-time, indicating a pro-
thrombotic effect of EC controls (data not shown), this effect was reversed by PTL060 
treatment. Similar findings were replicated using wild type porcine NPI alone, compared to 
PTL060 or PTL011 (Figure 2D). It should be noted that, compared to human EC in human 
blood, porcine NPI alone induce a shorter time to clot initiation in human blood.
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Detection of Thrombalexin (TLN) after kidney transplantation and reperfusion
Thrombalexin is able to bind to kidney endothelium following ex-vivo perfusion within 
preservation solution. We perfused NHP kidneys with UW solution alone, UW solution 
supplemented with PTL060 (2μM, 4μM and 8μM) and UW solution supplemented with 
PTL011 (4μM) and performed immunohistochemistry. After 1 hour ex-vivo, we detected 
RICS2 staining only from the PTL060 infused kidneys. The RICS2 staining patterns 
changed overtime: deposition was predominantly within the glomeruli at 1hr post infusion 
but detected in tubular area at 72 hr post-infusion (Figure S2).
As a membrane-localising anticoagulant, one of the primary safety concerns in using TLN 
was the possibility of systemic elution, resulting in an increased bleeding risk. We confirmed 
that there is no detectable TLN in circulation by flow cytometry using RICS2 antibody 
(Figure 3A), either in cell bound (whole blood), or in plasma (Figure 3B, detected by 
secondary PBMC capture). To evaluate its systemic effect, we performed TEG with whole 
blood and plasma samples from untreated and TLN-treated animals. As shown in Figure 3C, 
at 1-hour post-transplant samples from all animals show a variable prolonged coagulation 
time, although it should be noted that per our operative protocol, all animals receive IV 
heparin sulfate (100–200 units/kg) shortly before explantation of the donor kidney. 
Surgically, no difference in anastamotic bleeding was observed between TLN treated and 
untreated animals.
All TLN treated donor kidneys were perfused with TLN (4uM) in UW-solution, and 
received a secondary UW flush to eliminate any unbound TLN prior to implantation. Kidney 
biopsies from TLN treated animals, taken post reperfusion, were compared to those of 
untreated animals. TLN treated animals showed consistently positive TLN staining in the 
graft (Figure 3D), which was visible on post-transplant day 4 and still positive by POD9 
(Data not shown). These data suggest that the tested concentration of TLN (4uM) with UW-
solution localizes to the graft but does not induce systemic anti-coagulation.
The impact of localised anti-coagulation on histological evidence of AMR
Previously, we reported that early antibody-mediated rejection (AMR) in the sensitized 
rhesus after kidney transplantation was present, with half of the animals demonstrating 
histopathological evidence of TMA within the transplanted kidney within the first week 
post-transplant(12). We hypothesized that coagulation induced by donor-specific antibody 
(DSA) initiates TMA and thereby induces AMR. Interestingly, TLN treatment (n=3) did not 
prolong graft survival compared to all untreated controls (controls n = 7, Figure 4A). In 
order to investigate the effect of TLN on histological evidence of TMA, time matched 
controls (early rejectors, n = 4, graft survival: 1, 7 and 8 days) were compared to the TLN 
treated monkeys (n=3, graft survival: 4, 7 and 9 days). TLN treated animals showed 
significantly reduced (p=0.03) microvascular inflammation scores (MVI = glomerulitis, g 
score + peritubular capillaritis, ptc score; Figure 4B) and a trend of reduced C4d deposition 
in the graft (Figure 4C). Thus total Banff 2013 AMR scores were reduced in TLN-treated 
animals (Table 1), although this did not reach significance. TMA was also not entirely 
eliminated in the TLN treated group but it showed strong trend of reduction compared to the 
early rejector controls (p = 0.07; Figure 4D), platelet deposition – measured by CD61 
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staining – was also reduced in the treated group, compared to controls, as was fibrinogen 
staining by immunofluorescence (Figure 4E).
Systemic coagulation factors and complement activation after TLN treatment
Systemic haemoglobin levels and circulating platelet counts were not different between 
groups (Figure 5A). These data suggest that TLN reduces intragraft thrombosis but it does 
not alter any systemic effects - anemia or thrombocytopaenia - seen with systemic TMA. In 
order to demonstrate the efficacy of thrombin blockade by thrombalexin, we measured 
circulating vWF levels, as well as thrombin-anti-thrombin (TAT) complexes. (Figure 5B), no 
difference in circulating vWF was seen in treated animals, compared to untreated control, 
however there was a trend for reduced plasma TAT levels in the early post-operative course 
of the TLN treated animals, suggesting effective thrombin inhibition, however these data 
should be interpreted with caution in view of the limited availability of control plasma 
samples.
The role of thrombin in complement activation has been identified(13). To evaluate whether 
the complement activation cascade was affected by targeting thrombin via Thrombalexin, we 
measured serum C3a, C5b-9, C4d, and MBL. In general, there was a trend for reduced 
evidence of complement activation products in the first 24hours post-transplant in the TLN 
treated group, which was most evident, but not significant for serum C3a on day 1 (p=0.07) 
(Figure 5C).
Discussion
The use of an anticoagulant, in the form of anti-thrombin, to prevent TMA is a novel 
application. TMA is a poorly described phenomenon post kidney transplantation, although 
clinicians involved with positive crossmatch (HLAi) are familiar with this aggressive 
phenotype of AMR, which may necessitate dramatic intervention in order to prevent acute 
graft loss in the early post-operative period(14). TMA is a descriptive term, for the observed 
clinical presentation of microangiopathic haemolytic anaemia (MAHA), thrombocytopaenia 
and microvascular thrombosis occurring as a result of endothelial cell activation. It has a 
range of predisposing hereditary and acquired underlying causes, which are important to 
distinguish with respect to optimal treatment(15, 16). In renal transplantation, de novo 
histological evidence of TMA was found to be most commonly associated with C4d positive 
AMR (55%), of whom 84% had a high PRA. TMA is often considered to be a complement 
mediated disease(17), however it more accurately represents the interface between 
complement and coagulation(1).
The use of complement inhibition in the setting of highly sensitized kidney transplantation 
has gained considerable interest with the advent of anti-C5 inhibition with Eculizumab. 
Initial results in reducing AMR in highly sensitized kidney transplant recipients were very 
promising(18), and many case reports of the ability of complement inhibition to reverse 
severe AMR demonstrate great benefit to salvage grafts(19), although this is in the absence 
of long-term benefit(20), and may therefore represent the ability of complement inhibition to 
reverse early AMR features, which are associated with TMA.
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Systemic anticoagulation has, for the most part, been avoided in the immediate post-
operative period in kidney transplantation, as a result of the potential for increased bleeding 
risk, hence the demonstration of no systemic elution of drug, or change in time to clot 
formation (Figure 1). Alternative means to control the thrombotic process of TMA through 
inhibition or down regulation of coagulation are therefore of interest. Recombinant soluble 
thrombomodulin (TBM) – a co-factor of thrombin important for the down regulation of 
coagulation and inflammation - has been used to treat TMA in the setting of liver 
transplantation(21). The manipulation of the coagulation system has also been used in 
xenotransplantation, as exogenously administered coagulation factors (human prothrombin 
concentrate complex, or recombinant FVIIa)(22). Interestingly, the genetic manipulation of 
TBM expression on cells within the transplanted organ has shown promise in both 
mitigating the systemic thrombocytopaenia associated with TMA in 
xenotransplantation(23), as well as abrogating the activation of complement (24).
Our hypothesis was that TLN, as a topical anti-thrombin agent, would provide local 
protection of the kidney, or treated cells from the effects of thrombosis (Figure 2), as well as 
mitigate complement activation and, potentially down regulate inflammation and graft 
infiltration with adaptive immune cells. Thrombin itself has a role in both primary 
haemostasis –with respect to platelet activation, and secondary haemostasis, in which fibrin 
is crosslinked to form a stable haemostatic clot, which is later degraded by fibrinolysis. 
Previously, bivalirudin, a synthetic analog of hirudin currently in use in cardiac surgery, 
which is most analogous to the active element of TLN, has been demonstrated to decrease 
thrombin-induced platelet activation(25). The importance of platelet deposition in TMA, has 
previously been demonstrated with CD61 staining of platelets which was positive in TMA 
induced by CNI toxicity in kidney transplant recipients(26). In our study, the absence of 
platelet deposition, as demonstrated by the lack of CD61 positivity in the TLN treated 
kidney grafts supports a biological effect of thrombin inhibition with TLN to prevent platelet 
activation and deposition. Additionally, histology clearly demonstrated less fibrin deposition 
and a less histologically severe form of TMA (Figure 4).
The effect of thrombin on complement activation is currently a field of active study. It has 
been recognized that thrombin is an activator of complement at the level of C3 however, in 
addition, thrombin has also been shown to be able to cleave C5 directly, independent of C3 
(27), In our model, serum measurements of complement activation products, principally C3a 
showed a trend for lower levels in the immediate post-operative period (Figure 5), however 
this was a transient observation. In the kidney, evidence of complement activation, in the 
form of C4d deposition was somewhat lower (p = 0.09) in treated vs untreated animals, but 
this not significant. In addition, there was no histological difference in graft infiltrating cells, 
T-cell (CD3, CD4) or B-cell (CD20) (data not shown). Taken together, these data indicate a 
possible effect of thrombin-inhibition on complement activation, although this is not 
conclusive.
The lack of survival benefit in TLN treated animals, compared to controls, contrasts with 
previous findings in a sensitized rat model(10). This is likely to be attributable to a number 
of factors. Firstly, although a survival benefit in the rat model was demonstrated, all survival 
times, in the absence of any immunosuppression, were short: TLN increased the MST in the 
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rat model from 1.5d to 5.1. MST in our TLN treated group was 6.6 days, compared to 4.25d 
in the early rejector control group, and 18.7d with all controls. This may represent the dwell 
time of TLN on the cell-membrane target, and therefore period of efficacy.
Secondly, it may be a consequence of underdosing, although drug elution experiments (data 
not shown) suggest that effluent from the renal vein directly after TLN administration is 
positive for TLN after 4uM dosing. Alternatively, the expression of the compound on the 
cell membrane is insufficient to provide activity, either as a consequence of the dwell time 
on the cell surface, or as a result of cellular uptake. Repeated dosing of TLN is not possible, 
due to the route of administration arterially to the organ itself.
In present form the role of this compound remains to be established, although isolated 
treatment of the transplanted organ is a pragmatic option, particularly in light of the new role 
of ex-vivo normothermic perfusion treatments. A potential application of TLN may be, as 
Parajuli et al. advocate, as part of preventative strategies for patients at increased thrombotic 
risk (ie. Anti-phospholipid antibodies protein C & S deficiencies etc), this may be a 
protective strategy in the first 24 hours post-transplant (28) that avoids the management 
difficulties of post-operative anticoagulation.
Further study of the interactions between coagulation and complement may yield further 
evidence which would support combination therapy with Mirococept (cytotopic C3-
convertase inhibitor) in the perioperative setting, however these data are demonstrate 
promising efficacy, safety and detection of a novel agent within a large animal model.
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ABMR Acute Antibody Mediated rejection
EC Endothelial Cell
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IBMIR Instant Blood Mediated Inflammatory Reaction
MAHA Microangiopathic Haemolytic Anaemia
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NPI Neonatal Porcine Islets
TEG Thromboelastography
TLN Thrombalexin
TMA Thrombotic Microangiopathy
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Figure 1. 
A. Schematic illustration of the structure and binding site of Thrombalexin (PTL060; TLN). 
Thrombalexin is anchored to the cell membrane with a misorystoyl tail, and prevents 
activation of Thrombin (Factor IIa) via inhibition of both the active and exo-sites. Detection 
of Thrombalexin using RICS2 mAb (mouse anti-Thrombalexin), in both rhesus (B) and 
human (C) whole blood.
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Figure 2. 
Efficacy of Thombalexin (PTL060; TLN). A. Thromboelastography (TEG) using rhesus 
whole blood comparing adding TLN or HLL (PTL011, active Hirudin-like molecule) 
directly to blood, compared to kaolin control. B. TEG using human whole blood comparing 
kaolin control, Thombalexin (PTL060; TLN) or HLL (PTL011). C. TEG demonstrating 
efficacy of Thrombalexin treated EC, compared to HLL in prolonging time to clot initiation 
(r time, mins) compared to EC alone. PBS alone (no cell suspension) controls in black are 
shown for representative comparison. D. TEG demonstrating efficacy of Thrombalexin 
treated NPI, compared to HLL in prolonging time to clot initiation (r time, mins) compared 
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to NPI alone. NS>0.05, *p<0.05, **p<0.01, and ***p<0.001. PBS alone (no cell 
suspension) controls in black are shown for representative comparison.
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Figure 3. 
Systemic and In-situ detection of Thrombalexin (TLN) in kidney following transplantation 
A. Systemic detection of TLN following transplantation of a kidney infused with TLN at the 
time of retrieval in rhesus whole blood using RICS2 mAb. B. Systemic capture of TLN 
following transplantation of a kidney infused with TLN at the time of retrieval from rhesus 
plasma using an alternative source of cells (rhesus PBMC) & RICS2 mAb. C. Post-
transplantation TEG of rhesus whole blood. D. Post-transplant Immunofluoresence 
demonstrating the presence of Thombalexin (TLN) in 1hr post-reperfusion biopsy, and 
terminal kidney samples in TLN treated animals, compared to untreated controls.
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Figure 4. 
Post-transplant survival and histology after Thrombalexin (TLN) treatment of the donor 
kidney. A. Survival of TLN (4uM) treated kidneys, compared to untreated controls B. Banff 
(2013) Microvascular inflammation scores (glomerulitis + peritubular capillaritis) between 
time matched controls and TLN treated kidneys.
C. Banff (2013) C4d deposition between time matched controls and TLN treated kidneys. D. 
Histological thrombotic microangiopathy (TMA) scores between time matched controls and 
TLN treated kidneys. E. Histological evidence of platelet (CD61) deposition between time 
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matched controls and TLN treated kidneys and representative histological fibrinogen 
deposition between time matched controls and TLN treated kidneys. NS>0.05 and *p<0.05.
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Figure 5. 
Post-transplant systemic evidence of coagulation & complement inhibition. A. Systemic 
haemoglobin & platelet levels of TLN treated animals, compared to controls. B. Systemic 
(plasma) detected von Willebrand Factor (vWF) & Thrombin-anti-Thombin complexes 
(TAT) of TLN treated animals, compared to controls. C. Systemic detected complement 
products: C3a, C5b-9, C4d containing activation fragments & Mannose Binding Lectin 
(MBL) in TLN treated animals, compared to controls. *p<0.05.
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